COVID-19 vaccines unrelated to menstrual changes; Possible link between SSRIs and survival


The COVID-19 pandemic has been riddled with rumors and misinformation, some of which is intentional. The World Health Organization (WHO) has gone so far as to say there are two pandemics, COVID-19 and medical misinformation. Yet another rumor has circulated: COVID-19 vaccines cause changes in women’s menstrual cycles.

COVID-19 vaccines are not linked to menstrual changes

A UK study of 1,273 women found no correlation. Earlier studies suggested that a link was possible and should be investigated, but this new study supports the idea of ​​no association.

“We have not been able to pick up strong signals to support the idea that vaccines affect the timing or flow of menstrual cycles,” said Dr Victoria Male of Imperial College London. She added that more in-depth studies or studies in other countries might find links. “It is important to note that most people who report such a change after vaccination find that their periods return to normal in the next cycle. “

OK to receive flu and COVID-19 vaccines at the same time

Another study also found that it is safe to give people COVID-19 and flu shots at the same time. This study was published in The Lancet. Researchers have assigned 697 adults to receive their second dose of Pfizer-BioNTech vaccine or AstraZeneca-Oxford vaccine with one of three influenza vaccines for 2020Flu season 2021 (FluAd, Flucelvax or Flublok) or a placebo. Antibody responses were not adversely affected and most reactions were mild or moderate.

Lung cancer patients benefit from mRNA COVID-19 vaccines

Good news, a study has found that lung cancer patients who receive treatments that suppress their immune systems still benefit from COVID-19 mRNA vaccines. This small study was carried out on 306 patients with lung cancer in France, 70% of whom had received immunosuppressive treatments. Patients who had COVID-19 antibodies from a previous infection received an injection, but most received both. About 10% of the patients did not develop antibodies in response to the first two doses and received a third booster injection, which induced antibodies in all but three people who had blood diseases that adversely affect the blood. vaccine efficacy.

In the study, which lasted for seven months, only eight patients, or 2.6%, developed mild cases of COVID-19. The researchers say the trial was small and non-randomized, so more research is needed to confirm this.

People on SSRI antidepressants less likely to die from COVID-19

A study from the University of California, San Francisco found that people taking a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs), especially fluoxetine, were significantly less likely to die from COVID-19 than people in a matched control group. The data was analyzed from health records from 87 centers across the United States. The data came from nearly 500,000 patients, including 83,584 adults diagnosed with COVID-19 between January and September 2020. Of these patients, 3,401 received SSRIs.

“We can’t say if the drugs cause these effects, but statistical analysis shows a significant association,” Marina Sirota, Ph.D., associate professor of pediatrics and member of the Bakar Computational Health Sciences Institute (BCHSI) told UCSF. “There is power in the numbers. “

Research found that patients taking fluoxetine (sold under the brands Prozac and Sarafem) were 28% less likely to die from COVID-19, and patients taking either flueoxetine or fluvoxamine (brand names Luvox, Faverin, Fluvoxin) were 26% less likely to die. Of the group as a whole, patients taking an SSRI were 8% less likely to die from COVID-19 than the control group of matched patients. Other common brands of SSRIs include Celexa (citalopram), Lexapro (escitalopram), Paxil (paroxetine), and Zoloft (sertraline).


Comments are closed.